Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas

Pietro Quaglino, Nicola Pimpinelli, Emilio Berti, Piergiacomo Calzavara-Pinton, Giuseppe Alfonso Lombardo, Serena Rupoli, Mauro Alaibac, Ugo Bottoni, Angelo Carbone, Paolo Fava, Michele Fimiani, Angela Maria Mamusa, Stefano Titli, Pier Luigi Zinzani, Maria Grazia Bernengo

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

BACKGROUND: Mycosis fungoides (MF) is an indolent primary cutaneous T-cell lymphoma. To the authors' knowledge, no data currently are available regarding the evolution over time of the risk of developing specific pathways of disease progression. METHODS: This retrospective study analyzed 1422 patients with MF who were diagnosed and followed from 1975 through 2010 in 27 Italian Study Group for Cutaneous Lymphoma centers. The primary objectives were to ascertain the time course, pathways, and hazards risk trends of cutaneous/extracutaneous disease progression; to evaluate whether different tumor-lymph node-metastasis-blood (TNMB) stages have different pathways of disease progression; and to analyze differences between tumor-stage and erythrodermic MF with regard to clinical onset, disease evolution, and prognosis. The secondary objective was to provide a further validation for the revised International Society for Cutaneous Lymphomas and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (ISCL/EORTC) classification. RESULTS: The median follow-up was 14.5 years; stage progression occurred in 29.7% of patients and blood involvement was the most frequent extracutaneous site of disease progression. Patients with stage IA to stage IB disease demonstrated a steady low annual incidence of disease progression to tumor-stage (1%-2%); patients with stage IIA disease had a higher risk within the first years (up to 9.4%). Erythroderma evolved with a significantly higher frequency from patches/plaques (13.9%/28.2%) than tumors (P =.028 and P =.013, respectively). Hazards rates of extracutaneous involvement were low (<1%). The T-score was found to be associated with extracutaneous involvement site, tumor-stage disease with lymph node/visceral lesions, and erythroderma with blood involvement. TNMB classification and stage progression resulted as independent prognostic variables being detected on multivariate analysis; the type of extracutaneous involvement was found to affect survival. CONCLUSIONS: The data from the current study support the need for a stage-tailored follow-up, suggest that the classification of tumor-stage disease at a stage below erythroderma could be modified, and offer a further validation for the revised TNMB classification.

Original languageEnglish
Pages (from-to)5830-5839
Number of pages10
JournalCancer
Volume118
Issue number23
DOIs
Publication statusPublished - Dec 1 2012

Fingerprint

Mycosis Fungoides
Critical Pathways
Disease Progression
Lymphoma
Skin
Exfoliative Dermatitis
Neoplasms
Lymph Nodes
Neoplasm Metastasis
Cutaneous T-Cell Lymphoma
Advisory Committees
Skin Diseases
Multivariate Analysis
Retrospective Studies
Organizations
Survival

Keywords

  • classification
  • cutaneous T-cell lymphoma
  • erythroderma
  • multivariate analysis
  • mycosis fungoides
  • prognosis
  • tumor-lymph node-metastasis-blood (TNMB)
  • tumor-stage

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides : A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. / Quaglino, Pietro; Pimpinelli, Nicola; Berti, Emilio; Calzavara-Pinton, Piergiacomo; Alfonso Lombardo, Giuseppe; Rupoli, Serena; Alaibac, Mauro; Bottoni, Ugo; Carbone, Angelo; Fava, Paolo; Fimiani, Michele; Mamusa, Angela Maria; Titli, Stefano; Zinzani, Pier Luigi; Bernengo, Maria Grazia.

In: Cancer, Vol. 118, No. 23, 01.12.2012, p. 5830-5839.

Research output: Contribution to journalArticle

Quaglino, P, Pimpinelli, N, Berti, E, Calzavara-Pinton, P, Alfonso Lombardo, G, Rupoli, S, Alaibac, M, Bottoni, U, Carbone, A, Fava, P, Fimiani, M, Mamusa, AM, Titli, S, Zinzani, PL & Bernengo, MG 2012, 'Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas', Cancer, vol. 118, no. 23, pp. 5830-5839. https://doi.org/10.1002/cncr.27627
Quaglino, Pietro ; Pimpinelli, Nicola ; Berti, Emilio ; Calzavara-Pinton, Piergiacomo ; Alfonso Lombardo, Giuseppe ; Rupoli, Serena ; Alaibac, Mauro ; Bottoni, Ugo ; Carbone, Angelo ; Fava, Paolo ; Fimiani, Michele ; Mamusa, Angela Maria ; Titli, Stefano ; Zinzani, Pier Luigi ; Bernengo, Maria Grazia. / Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides : A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. In: Cancer. 2012 ; Vol. 118, No. 23. pp. 5830-5839.
@article{20dcfa2298c24ad2b63c30bdca5f9664,
title = "Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas",
abstract = "BACKGROUND: Mycosis fungoides (MF) is an indolent primary cutaneous T-cell lymphoma. To the authors' knowledge, no data currently are available regarding the evolution over time of the risk of developing specific pathways of disease progression. METHODS: This retrospective study analyzed 1422 patients with MF who were diagnosed and followed from 1975 through 2010 in 27 Italian Study Group for Cutaneous Lymphoma centers. The primary objectives were to ascertain the time course, pathways, and hazards risk trends of cutaneous/extracutaneous disease progression; to evaluate whether different tumor-lymph node-metastasis-blood (TNMB) stages have different pathways of disease progression; and to analyze differences between tumor-stage and erythrodermic MF with regard to clinical onset, disease evolution, and prognosis. The secondary objective was to provide a further validation for the revised International Society for Cutaneous Lymphomas and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (ISCL/EORTC) classification. RESULTS: The median follow-up was 14.5 years; stage progression occurred in 29.7{\%} of patients and blood involvement was the most frequent extracutaneous site of disease progression. Patients with stage IA to stage IB disease demonstrated a steady low annual incidence of disease progression to tumor-stage (1{\%}-2{\%}); patients with stage IIA disease had a higher risk within the first years (up to 9.4{\%}). Erythroderma evolved with a significantly higher frequency from patches/plaques (13.9{\%}/28.2{\%}) than tumors (P =.028 and P =.013, respectively). Hazards rates of extracutaneous involvement were low (<1{\%}). The T-score was found to be associated with extracutaneous involvement site, tumor-stage disease with lymph node/visceral lesions, and erythroderma with blood involvement. TNMB classification and stage progression resulted as independent prognostic variables being detected on multivariate analysis; the type of extracutaneous involvement was found to affect survival. CONCLUSIONS: The data from the current study support the need for a stage-tailored follow-up, suggest that the classification of tumor-stage disease at a stage below erythroderma could be modified, and offer a further validation for the revised TNMB classification.",
keywords = "classification, cutaneous T-cell lymphoma, erythroderma, multivariate analysis, mycosis fungoides, prognosis, tumor-lymph node-metastasis-blood (TNMB), tumor-stage",
author = "Pietro Quaglino and Nicola Pimpinelli and Emilio Berti and Piergiacomo Calzavara-Pinton and {Alfonso Lombardo}, Giuseppe and Serena Rupoli and Mauro Alaibac and Ugo Bottoni and Angelo Carbone and Paolo Fava and Michele Fimiani and Mamusa, {Angela Maria} and Stefano Titli and Zinzani, {Pier Luigi} and Bernengo, {Maria Grazia}",
year = "2012",
month = "12",
day = "1",
doi = "10.1002/cncr.27627",
language = "English",
volume = "118",
pages = "5830--5839",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides

T2 - A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas

AU - Quaglino, Pietro

AU - Pimpinelli, Nicola

AU - Berti, Emilio

AU - Calzavara-Pinton, Piergiacomo

AU - Alfonso Lombardo, Giuseppe

AU - Rupoli, Serena

AU - Alaibac, Mauro

AU - Bottoni, Ugo

AU - Carbone, Angelo

AU - Fava, Paolo

AU - Fimiani, Michele

AU - Mamusa, Angela Maria

AU - Titli, Stefano

AU - Zinzani, Pier Luigi

AU - Bernengo, Maria Grazia

PY - 2012/12/1

Y1 - 2012/12/1

N2 - BACKGROUND: Mycosis fungoides (MF) is an indolent primary cutaneous T-cell lymphoma. To the authors' knowledge, no data currently are available regarding the evolution over time of the risk of developing specific pathways of disease progression. METHODS: This retrospective study analyzed 1422 patients with MF who were diagnosed and followed from 1975 through 2010 in 27 Italian Study Group for Cutaneous Lymphoma centers. The primary objectives were to ascertain the time course, pathways, and hazards risk trends of cutaneous/extracutaneous disease progression; to evaluate whether different tumor-lymph node-metastasis-blood (TNMB) stages have different pathways of disease progression; and to analyze differences between tumor-stage and erythrodermic MF with regard to clinical onset, disease evolution, and prognosis. The secondary objective was to provide a further validation for the revised International Society for Cutaneous Lymphomas and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (ISCL/EORTC) classification. RESULTS: The median follow-up was 14.5 years; stage progression occurred in 29.7% of patients and blood involvement was the most frequent extracutaneous site of disease progression. Patients with stage IA to stage IB disease demonstrated a steady low annual incidence of disease progression to tumor-stage (1%-2%); patients with stage IIA disease had a higher risk within the first years (up to 9.4%). Erythroderma evolved with a significantly higher frequency from patches/plaques (13.9%/28.2%) than tumors (P =.028 and P =.013, respectively). Hazards rates of extracutaneous involvement were low (<1%). The T-score was found to be associated with extracutaneous involvement site, tumor-stage disease with lymph node/visceral lesions, and erythroderma with blood involvement. TNMB classification and stage progression resulted as independent prognostic variables being detected on multivariate analysis; the type of extracutaneous involvement was found to affect survival. CONCLUSIONS: The data from the current study support the need for a stage-tailored follow-up, suggest that the classification of tumor-stage disease at a stage below erythroderma could be modified, and offer a further validation for the revised TNMB classification.

AB - BACKGROUND: Mycosis fungoides (MF) is an indolent primary cutaneous T-cell lymphoma. To the authors' knowledge, no data currently are available regarding the evolution over time of the risk of developing specific pathways of disease progression. METHODS: This retrospective study analyzed 1422 patients with MF who were diagnosed and followed from 1975 through 2010 in 27 Italian Study Group for Cutaneous Lymphoma centers. The primary objectives were to ascertain the time course, pathways, and hazards risk trends of cutaneous/extracutaneous disease progression; to evaluate whether different tumor-lymph node-metastasis-blood (TNMB) stages have different pathways of disease progression; and to analyze differences between tumor-stage and erythrodermic MF with regard to clinical onset, disease evolution, and prognosis. The secondary objective was to provide a further validation for the revised International Society for Cutaneous Lymphomas and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (ISCL/EORTC) classification. RESULTS: The median follow-up was 14.5 years; stage progression occurred in 29.7% of patients and blood involvement was the most frequent extracutaneous site of disease progression. Patients with stage IA to stage IB disease demonstrated a steady low annual incidence of disease progression to tumor-stage (1%-2%); patients with stage IIA disease had a higher risk within the first years (up to 9.4%). Erythroderma evolved with a significantly higher frequency from patches/plaques (13.9%/28.2%) than tumors (P =.028 and P =.013, respectively). Hazards rates of extracutaneous involvement were low (<1%). The T-score was found to be associated with extracutaneous involvement site, tumor-stage disease with lymph node/visceral lesions, and erythroderma with blood involvement. TNMB classification and stage progression resulted as independent prognostic variables being detected on multivariate analysis; the type of extracutaneous involvement was found to affect survival. CONCLUSIONS: The data from the current study support the need for a stage-tailored follow-up, suggest that the classification of tumor-stage disease at a stage below erythroderma could be modified, and offer a further validation for the revised TNMB classification.

KW - classification

KW - cutaneous T-cell lymphoma

KW - erythroderma

KW - multivariate analysis

KW - mycosis fungoides

KW - prognosis

KW - tumor-lymph node-metastasis-blood (TNMB)

KW - tumor-stage

UR - http://www.scopus.com/inward/record.url?scp=84869502113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869502113&partnerID=8YFLogxK

U2 - 10.1002/cncr.27627

DO - 10.1002/cncr.27627

M3 - Article

C2 - 22674564

AN - SCOPUS:84869502113

VL - 118

SP - 5830

EP - 5839

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -